Authors

Main Content

Top Content

Directory of Authors from the Journal and their last article.

Harry G RittenhouseView Articles

Volume 9, Number 3Review Articles

Twenty Years of PSA: From Prostate Antigen to Tumor Marker

Diagnostic Update

Gabriela De AngelisStephen D MikolajczykHarry G RittenhouseAxel SemjonowL Blair Shamel

The measurement of prostate-specific antigen in serum is credited with dramatic advances in the early detection of men with prostatic carcinoma. This report summarizes the history of biochemical research and the current understanding and application of prostate-specific antigen in prostate cancer diagnostics. [Rev Urol. 2007;9(3):113-123]

Prostate cancerProstate-specific antigenHuman kallikrein

Harry W RobertsView Articles

Volume 17, Number 2Book Reviews

A Review of Transplantation Practice of the Urologic Organs: Is It Only Achievable for the Kidney?

Treatment Update

Jack Donati-BourneHarry W RobertsYaseen RajjoubRobert A Coleman

Transplantation is a viable treatment option for failure of most major organs. Within urology, transplantation of the kidney and ureter are well documented; however, evidence supporting transplantation of other urologic organs is limited. Failure of these organs carries significant morbidity, and transplantation may have a role in management. This article reviews the knowledge, research, and literature surrounding transplantation of each of the urologic organs. Transplantation of the penis, testicle, urethra, vas deferens, and bladder is discussed. Transplantation attempts have been made individually with each of these organs. Penile transplantation has only been performed once in a human. Testicular transplantation research was intertwined with unethical lucrative pursuits. Interest in urethra, bladder, and vas deferens transplantation has decreased as a result of successful surgical reconstructive techniques. Despite years of effort, transplantations of the penis, testicle, urethra, vas deferens, and bladder are not established in current practice. Recent research has shifted toward techniques of reconstruction, tissue engineering, and regenerative medicine. [Rev Urol. 2015;17(2):69–77 doi: 10.3909/riu0659] © 2015 MedReviews®, LLC

UrologyTransplantationReconstructionTissue engineering

Hedyeh EbrahimiView Articles

Volume 23, Number 2Case of the Quarter

Case of the Quarter: Kaposi Sarcoma in a Patient With Testicular Germ Cell Tumor and HIV: A Case Report and Literature Review

Daniela V. CastroDonald HannounTanya B. DorffAlexander Chehrazi-RaffleWesley YipAbhishek TripathiBenjamin MercierRegina Barragan-CarrilloHedyeh EbrahimiSalvador Jaime-Casas

Testicular germ cell tumors are the leading cause of cancer in male patients 15 to 39 years old. Extensive treatments are available, and the regimen of choice depends on clinical, laboratory, and histopathologic characteristics. Patients with HIV are at increased risk of developing solid malignancies, including testicular germ cell tumors. All patients with HIV should start on highly active antiretroviral therapy, but the drug interactions between chemotherapy for testicular germ cell tumor and highly active antiretroviral therapy have not been extensively evaluated. This case review highlights the importance of optimal therapeutic agent selection in patients with HIV and solid malignancies.

Testicular neoplasmGerm cellHIVTesticular neoplasmsSarcoma

Heinz G NicolaiView Articles

Volume 18, Number 2Review Articles

Challenges and Opportunities in Radiation-induced Hemorrhagic Cystitis

Therapeutic Strategy Update

Michael B ChancellorBernadette MM ZwaansHeinz G NicolaiLaura E Lamb

As diagnosis and treatment of cancer is improving, medical and social issues related to cancer survivorship are becoming more prevalent. Hemorrhagic cystitis (HC), a rare but serious disease that may affect patients after pelvic radiation or systemic chemotherapy, has significant unmet medical needs. Although no definitive treatment is currently available, various interventions are employed for HC. Effects of nonsurgical treatments for HC are of modest success and studies aiming to control radiation-induced bladder symptoms are lacking. In this review, we present current and advanced therapeutic strategies for HC to help cancer survivors deal with long-term urologic health issues. [Rev Urol. 2016;18(2):57-65 doi: 10.3909/riu0700] © 2016 MedReviews®, LLC

Hemorrhagic cystitisRadiation-induced cystitisHematuriaCancer survivorship

Heinz NicolaiView Articles

Volume 17, Number 3Meeting Reviews

Highlights From the 2015 American Urological Association Annual Meeting, May 15-19, 2015, New Orleans, LA

Best of the 2015 AUA Annual Meeting

Dean G AssimosEllen ShapiroAlan W PartinMichael B ChancellorStacy LoebJ Curtis NickelMichael A GorinMichael K BrawerHeinz NicolaiÁine Goggins

[Rev Urol. 2015;17(3):179-189 doi:10.3909/riu0681] © 2015 MedReviews®, LLC

Active surveillanceHypospadias4KscoreProlarisStress urinary incontinencePatient phenotypingChronic pelvic pain syndromeEXO106 testMRI/US fusion biopsyOxalobacter formigenesUreteroscopic stone removalDecipher assayRadiation cystitisOccult tethered cord syndromeMRI-guided biopsy

Helen SadriView Articles

Volume 11, Number 3Review Articles

Screening for Prostate Cancer: A Review of the ERSPC and PLCO Trials

Management Update

Herbert LeporSamir S TanejaBob DjavanElisabeth EckersbergerJulia FinkelsteinHelen SadriMarkus Margreiter

The advent of prostate-specific antigen (PSA) testing in the early 1980srevolutionized the diagnosis of prostate cancer. As a result of PSA testing,there has been a surge in the number of prostate cancer diagnoses. Thisreview examines the results of 2 recent landmark trials that studied the effectof screening on prostate cancer mortality: the European Randomized Study ofScreening for Prostate Cancer (ERSPC) and the US-based Prostate, Lung,Colorectal, and Ovarian (PLCO) Cancer Screening Trial.[Rev Urol. 2009;11(3):127-133 doi: 10.3909/riu0474]

PSA screeningEuropean Randomized Study of Screening for Prostate Cancer(ERSPC)Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial

Hemant Chaparala (4)View Articles

Volume 17, Number 2Case Review

Long-term Survival From Muscle-invasive Bladder Cancer With Initial Presentation of Symptomatic Cerebellar Lesion: The Role of Selective Surgical Extirpation of the Primary and Metastatic Lesion

Ganesh K KarthaJoseph SanfrancescoEsther UdojiHemant Chaparala (4)Donna HanselJ Stephen Jones

A 59-year-old man was diagnosed with urothelial carcinoma involving an isolated cerebellar metastasis after presenting to the emergency department for headache complaints. After selective surgical excision of the symptomatic brain lesion and delayed cystectomy due to intractable hematuria, he survived 11 years without evidence of recurrence or subsequent systemic chemotherapy. He eventually expired after delayed recurrence in the lung, supraclavicular lymph node, and brain. To our knowledge, this is the only case of prolonged survival from urothelial carcinoma after selective surgical extirpation of the primary and metastatic lesion without subsequent systemic chemotherapy. [Rev Urol. 2015;17(2):106-109 doi: 10.3909/riu0643] © 2015 MedReviews®, LLC

Urothelial carcinomaBladder cancerMetastasisCystectomy

Herbert LeporView Articles
Hersh M TrivediView Articles

Volume 22, Number 2Case Review

First Do No Harm: A Cautious, Risk-adapted Approach to Testicular Cancer Patients

Nirmish SinglaAditya BagrodiaHersh M TrivediJohn LafinDavid FetzerPayal Kapur

Current guidelines regarding treatment for germ-cell tumors (GCTs) emphasizes cautious progression focusing on stage-specific treatments. Presented herein is the case of a 30-year-old man who, through monitoring of serum alpha-fetoprotein (AFP) levels and surveillance imaging, avoided excessive treatment. This case demonstrates how an experienced clinician, familiar with natural history of GCTs, can appropriately classify level of risk and allow a patient to preserve natural fertility. Furthermore, we highlight the potential for miRNA analysis in staging and management of GCTs. This case serves to underscore the importance of acting with caution in the pursuit of the best outcome for our patients. [Rev Urol. 2020;22(2):85–89] © 2020 MedReviews®, LLC

Hilgard AckermannView Articles

Volume 19, Number 4Case Review

Cycling Trauma as a Cause of Arterial Priapism in Children and Teenagers

Aldo Franco De RoseIrene ParaboschiGuglielmo ManticaAlexander SzpytkoHilgard AckermannGiovanni De CaroCarlo TerroneGirolamo Mattioli

Bicycle riding has multiple beneficial cardiovascular effects; however, it is a well-documented source of significant urologic injuries. Priapism is a rare condition in children, and occurs primarily because of congenital hematologic diseases or adverse drug reactions. A pediatric clinical case and literature review of a high-flow priapism secondary to cycling trauma is described here to highlight their etiopathologic correlation. Bicycle riding trauma is a rare but possible cause of high-flow priapism in children, and a high index of suspicion should ensure appropriate management. [Rev Urol. 2017;19(4):273–277 doi: 10.3909/riu0768] © 2018 MedReviews®, LLC

PediatricTraumaPriapismCycling

Hinde El FatemiView Articles

Volume 9, Number 1Reviews in Urology

Solitary Fibrous Tumor of the Kidney: A Case Report and Review of the Literature

Case Review

Imane KamaouiAfaf AmartiSanae BennisLaila ChbaniHinde El FatemiTaoufik HarmouchFadl TaziKaoutar Znati

A solitary fibrous tumor (SFT) is an unusual spindle cell neoplasm that usually occurs in the pleura but has recently been described in diverse extrapleural sites. Urogenital localization is rare, and only 19 cases of SFT of the kidney have been described. We report a case of a large SFT clinically thought to be renal cell carcinoma arising in the kidney of a 70-year-old man. The tumor was well circumscribed and composed of a mixture of spindle cells and dense collagenous bands, with areas of necrosis or cystic changes noted macroscopically and microscopically. Immunohistochemical studies revealed reactivity for CD34, CD99, and Bcl-2 protein, with no staining for keratin, S-100 protein, or muscle markers, confirming the diagnosis of SFT. This tumor is benign in up to 90% of cases. The immunohistochemical study is the key to diagnosis. [Rev Urol. 2007;9(1):36-40]

KidneyImmunohistochemical studyRenal neoplasmSpindle cells

Hinde ElfatemiView Articles

Volume 13, Number 3Case Review

Concomitant Sertoli and Leydig Cell Tumor of the Testis: A Case Report

Abdelhak KhalloukYounes AhallalMohamed Jamal El FassiMoulay Hassan FarihMohamed Fadl TaziElmehdi TaziHinde ElfatemiMohcine Bendahou

A rare intratubular gonadal stromal tumor was present in the testis of a 45-year-old man who was admitted to our hospital with the chief complaint of gradual enlargement of the left testis. Tumoral markers were negative and no extension was observed. The tumor comprised an intratubular mixture of two types of tumor cells with intercellular junctions: the predominant tumor cells were consistent with a Sertoli cell origin and cells comprising the minor population consistent with a Leydig cell origin. The patient is disease free after 6-month follow-up. The case is considered to be a testicular mixed tubular Sertoli-Leydig cell tumor. It highlights a rare type of primary tumor of the testis that features a good prognosis. [Rev Urol. 2011;13(3):173-175 doi:10.3909/riu0495] © 2011 MedReviews®, LLC

Hiroshi AzumaView Articles
Hiten D. PatelView Articles

Volume 23, Number 3Prostate Cancer

Advances in Radical Prostatectomy: A Narrative Review

Austin DryschKathryn E. FinkChalairat Suk-OuichaiMitchell M. HuangKent T. PerryHiten D. PatelAshley E. Ross

Radical prostatectomy (RP) is the mainstay surgical treatment for men with localized prostate cancer. The use of robot-assisted RP (RARP) has specifically allowed for the development of novel techniques to improve postoperative quality of life for patients.

Prostatic neoplasmsProstatectomyRobotic-assisted surgeryrobotic surgical procedures

Hitoshi MasudaView Articles
Howard M SandlerView Articles
Howard R HigleyView Articles
Howard R SouleView Articles
Hsin-Tzu LiuView Articles

Volume 12, Number 3Review Articles

Can Urinary Nerve Growth Factor Be a Biomarker for Overactive Bladder?

Diagnostic Update

Michael B ChancellorHann-Chorng KuoHsin-Tzu Liu

The clinical diagnosis of overactive bladder (OAB) greatly varies and is based on subjective symptoms. A more objective method to diagnose and assess therapeutic outcome in OAB patients, especially for health care providers not trained in urology, needs to be found. Evidence has shown that urinary proteins such as nerve growth factor (NGF) and prostaglandin E2 levels increase in patients with OAB, bladder outlet obstruction, and detrusor overactivity. Urinary NGF level increases physiologically in normal subjects at urge to void, but increases pathologically in OAB patients at a small bladder volume and with a sensation of urgency. Recent studies have shown that patients with OAB dry and OAB wet have significantly higher urinary NGF levels compared with control groups and patients with increased bladder sensation. Urinary NGF levels decrease after antimuscarinic therapy and further decrease after detrusor botulinum toxin injections in refractory OAB. Urinary NGF level could be a potential biomarker for diagnosis of OAB and assessment of the therapeutic effect of antimuscarinic therapy. The latest medical advances in this field are reviewed herein. [Rev Urol. 2010;12(2/3):e69-e77 doi: 10.3909/riu0432]

BiomarkersOveractive bladderUrinary proteinsNerve growth factor

Hugh J LaveryView Articles

Volume 20, Number 3Original Research

Histologic Changes in Prostate Cancer Detected Subsequent to the 2012 United States Preventive Services Task Force (USPSTF) Prostate Cancer Screening Recommendation

Ann E AndersonCarl A OlssonHugh J LaveryDeepak Kapoor

We report changes in the histopathology of prostate cancer diagnosed in a large urology group practice after the final United States Preventive Services Task Force (USPSTF) Grade D recommendation against prostate-specific antigen screening. All prostate biopsies performed from 2011 through 2015 in a large urology group practice were retrospectively reviewed; 2012 was excluded as a transition year. The changes in biopsy data in years following the USPSTF decision (2013-2015) were then compared with baseline (2011). A total of 10,944 biopsies were evaluated during the study period. Positive biopsy rates rose from 39.1% at baseline to 45.2% in 2015 (P < 0.01) with a marked shift toward more aggressive cancer throughout the study period. The absolute number of patients presenting with Gleason Grade Group 4 or 5 increased from 155/year at baseline to 231, 297, and 285 in 2013, 2014, and 2015, respectively (P < 0.05), unrelated to age or racial changes over time. Black men represented 16% of the cohort. Since the USPSTF recommendation against prostate cancer screening, trends toward a substantial upward grade migration and increased volume of cancers were noted in a cohort of nearly 11,000 patients in a real- world clinical practice. Additionally, continuing reductions in cancer detection in the United States may exacerbate these trends. [Rev Urol. 2018;20(3):125–130 doi: 10.3909/riu0815] © 2018 MedReviews®, LLC

Prostate cancerProstate cancer screeningHistopathologygrade migration